Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized, Open-Label Phase II/III Study, To Compare The Efficacy Of NBTXR3, Implanted As Intratumor Injection And Activated By Radiotherapy, Versus Radiotherapy Alone In Patients With Locally Advanced Soft Tissue Sarcoma Of The Extremity And Trunk Wall

NCT02379845 is registered in ClinicalTrials.gov with Nanobiotix as lead sponsor.

NCT NCT02379845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02379845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized, Open-Label Phase II/III Study, To Compare The Efficacy Of NBTXR3, Implanted As Intratumor Injection And Activated By Radiotherapy, Versus Radiotherapy Alone In Patients With Locally Advanced Soft Tissue Sarcoma Of The Extremity And Trunk Wall
Lead sponsor
Nanobiotix
Phase
Phase 2/3
Overall status
Completed
Start date
March 3, 2015
Completion date
September 20, 2020
Enrollment
180 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

adult soft tissue sarcoma